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Letter to the editor
Veno-occlusive disease of the liver
induced by gemcitabine
We report the case of a 48-year-old female patient suffering
from non-small-cell lung cancer (NSCLC) with bone metastasis
who developed hepatic veno-occlusive disease (VOD) after
beeing treated with gemcitabine (GemzarK, Lilly, France).
Gemcitabine is a novel analogue of deoxycytodine which inhib-
its DNA synthesis and has been shown to produce objective
tumor response in a variety of cancers, e.g., NSCLC, pancre-
atic cancer, ovarian cancer, bladder cancer etc. This drug ap-
pears to be well tolerated. The major dose-limiting side effect
seems to be myelosupression, other common adverse effects
WHO 3 and 4 include transient elevation of hepatic enzymes
(not associated with dose or treatment duration), nausea und
vomiting [1].
The patient received a total of 11 applications of gemcita-
bine (1000 mg/m" as a 30 minute intravenous infusion once
weekly for three weeks, then 1 week off) over a period of fifteen
weeks. Because of bone pain additional analgetic oral medica-
tion with morphine sustained release and naproxen was ad-
ministered. During gemcitabine therapy no dose-limiting tox-
icity was observed. At the beginning of the therapy there was
no sign of liver function impairment or liver metastasis. After
seven applications a partial response in the primary tumor site
and in the mediastinal lymph node metastasis were noted.
Unexpectedly, the patient was hospitalized one week after the
last dose of gemcitabine due to nausea, vomiting, jaundice,
right upper quadrant pain and confusion. She was found to
have a decreased platelet count (9000/ul), liver tests revealed
a 10-fold increase in ASAT and five-fold increase in total
bilirubin. The abdominal ultrasound showed a thickening of
the gallbladder and perihepatic ascites without hepatomegaly
or liver metastasis. Six days after admission the patient devel-
oped progressive liver failure which resulted in hepatic coma.
She died two days later. The autopsy revealed typical findings
of veno-occlusive disease with occlusion of the terminal hepatic
venules, sinusoidal congestion and zone 3 hepatocyte necrosis
[2]. No hepatomegaly was found. Histologically rare tumor cell
deposits could be detected. The presence of portal lymphoid
infiltrates and the serological evidence of hepatitis C (HCV)
infection at death and in serum collected six months earlier
account for chronic HCV infection.
Several groups have reported various risk factors associated
with development of veno-occlusive disease after high dose
chemotherapy and bone marrow transplantation (BMT) [3].
One groupe related VOD to pre-transplant infection by HCV
[4]. In our patient, preexisting HCV infection might represent
a risk factor for developping VOD, due to an increased suscept-
ibility of hepatocytes to the toxic effect of cytoreductive therapy.
In the pathogenesis, endothelial injury through chemotherapy
would cause capillary leakage and activation of the coagula-
tion cascade, resulting in VOD.
The majority of cases of VOD occur secondary to high dose
chemotherapy with or without irradiation in patients under-
going BMT [5]. Additionally, a few reports have been published
on VOD in patients receiving non transplant dosage of chemo-
therapy (e.g., low dose cyclophosphamid, actinomycin D,
6-thioguanin, etc.) or following ingestion of pyrrolizidine alka-
loid-containing plants.
To our knowledge, this is the first report of hepatic veno-
occlusive disease associated with gemcitabine.
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